Allogenic V9V2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
Allogenic V9V2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
复制标题
DOI：
10.1186/s40425-019-0501-8
复制
发表时间：
2019-02-08
影响因子：
10.9
通讯作者：
Yin, Zhinan
中科院分区：
文献类型：
--
作者：
Alnaggar, Mohammed;Xu, Yan;Yin, Zhinan
背景胆管癌（cholangiocarcinoma，CCA）是一种高度侵袭性和致死性的肿瘤。CCA发生在胆管的上皮细胞中。由于发病率的增加，CCA占所有胃肠道恶性肿瘤的3%。除了手术、化疗和放疗等癌症综合治疗外，在过去几年中，细胞免疫治疗发挥了越来越重要的作用。病例介绍一位30岁男性（www.clinicaltrials.gov/ ID：NCT 02425735）因胆管癌（IV期）肝移植术后复发纵隔淋巴结转移而被确诊。在他的治疗过程中，他仅在2017年8月至2018年2月期间接受了同种异体T细胞免疫治疗（共8次输注）。从健康供体外周血单个核细胞（PBMCs）中扩增T细胞，并将4 × 10（8）个细胞过继转移至患者体内。结论在上述病例报告中，我们证实了同种异体T细胞治疗对接受肝移植的胆管癌（IV期）患者术后复发纵隔淋巴结转移无不良反应。我们观察到，同种异体T细胞治疗积极调节患者的外周免疫功能，消除肿瘤活性，改善生活质量，延长寿命。经8次T细胞处理后，淋巴结的大小显著减小，活性耗尽。本研究结果提示，同种异体T细胞免疫疗法有望成为治疗CCA的有效药物。
BackgroundCholangiocarcinoma (CCA) is a highly aggressive and fatal tumor. CCA occurs in the epithelial cells of bile ducts. Due to increasing incidences, CCA accounts for 3% of all gastrointestinal malignancies. In addition to comprehensive treatments for cancer, such as surgery, chemotherapy, and radiotherapy, during the past few years, cellular immunotherapy has played an increasingly important role. As a result of our research, we have discovered the T cell-based immunotherapy for CCA.Case presentationA 30-year-old male (https://www.clinicaltrials.gov/ ID: NCT02425735) was diagnosed with recurrent mediastinal lymph node metastasis after liver transplantation because of Cholangiocarcinoma (stage IV). In the course of his therapy sessions, he only received allogenic T cell immunotherapy from August, 2017 through February, 2018 (8 infusions in total). T cells were expanded from peripheral blood mononuclear cells (PBMCs) of healthy donor, and 4x10(8) cells were adoptive transferred to the patient.ConclusionIn the above case report of the Cholangiocarcinoma (stage IV) patient who had received liver transplantation and afterward was diagnosed with recurrent mediastinal lymph node metastasis, we clinically proved that allogenic T cell treatment had no adverse effects. We observed that allogenic T cell treatments positively regulated peripheral immune functions of the patient, depleted tumor activity, improved quality of life, and prolonged his life span. After 8 T cell treatments, the size of lymph nodes was remarkably reduced with activity depletion. This clinical work suggested that allogenic T cell immunotherapy could be developed into a promising therapy drug for CCA.